Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

BACKGROUND: Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients with baseline platelet counts ≥100 × 10(9)/L in phase III studies. The most comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Talpaz, Moshe, Paquette, Ronald, Afrin, Lawrence, Hamburg, Solomon I, Prchal, Josef T, Jamieson, Katarzyna, Terebelo, Howard R, Ortega, Gregory L, Lyons, Roger M, Tiu, Ramon V, Winton, Elliott F, Natrajan, Kavita, Odenike, Olatoyosi, Claxton, David, Peng, Wei, O’Neill, Peter, Erickson-Viitanen, Susan, Leopold, Lance, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176265/
https://www.ncbi.nlm.nih.gov/pubmed/24283202
http://dx.doi.org/10.1186/1756-8722-6-81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176265/
https://www.ncbi.nlm.nih.gov/pubmed/24283202
http://dx.doi.org/10.1186/1756-8722-6-81

Ejemplares similares